Roche Holding suspended recruitment of patients in a late-stage trial of Avastin after data showed the cancer drug's risks outweigh benefits when used in combination with MabThera and CHOP chemotherapy in patients with diffuse large B-cell lymphoma. The drugmaker said the findings do not affect Avastin's approved indications.

Full Story:

Related Summaries